/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.
FDA's vaccines office is now headed by Peter Marks after the agency's top two vaccine officials questioned the need for booster doses last month as they head toward the exit later this fall. Houston biotech incubator Sporos Biosciences snagged ex-Ovid Therapeutics Chief Medical Officer Amit Rakhit as its new CEO. In spinning off its gene therapy unit, Amicus' CEO will head to the new company being launched via a SPAC.